Ethnic differences in statin disposition

Clinical Pharmacology and Therapeutics

Volumn 78, Issue 4, 2005, Pages 311-316

  Tirona, Rommel G ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ASIAN; BODY WEIGHT; CENTRAL AMERICA; CHINESE; DIETARY INTAKE; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFECT; DRUG ELIMINATION; DRUG EXPOSURE; DRUG MECHANISM; DRUG TISSUE LEVEL; ENVIRONMENTAL FACTOR; ETHNOLOGY; FIRST PASS EFFECT; GENETIC VARIABILITY; HISPANIC; HUMAN; INDIAN; MALAYSIA; NOTE; PLASMA; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SINGAPORE; UNITED STATES;

ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTESTINAL ABSORPTION; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRIMIDINES; SULFONAMIDES;

EID: 25844440854     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.07.006     Document Type: Note

References (45)

1. E. Lee, S. Ryan, B. Birmingham, J. Zalikowski, R. March, H. Ambrose Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment Clin Pharmacol Ther 78 2005 330 341
2. K. Kim, J.A. Johnson, H. Derendorf Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms J Clin Pharmacol 44 2004 1083 1105
3. Crestor (rosuvastatin) [package insert] 2005 AstraZeneca London
4. P.D. Martin, M.J. Warwick, A.L. Dane, C. Brindley, T. Short Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers Clin Ther 25 2003 2553 2563
5. P.D. Martin, M.J. Warwick, A.L. Dane, S.J. Hill, P.B. Giles, P.J. Phillips Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers Clin Ther 25 2003 2822 2835
6. T. Prueksaritanont, C. Tang, Y. Qiu, L. Mu, R. Subramanian, J.H. Lin Effects of fibrates on metabolism of statins in human hepatocytes Drug Metab Dispos 30 2002 1280 1287
7. D.W. Schneck, B.K. Birmingham, J.A. Zalikowski, P.D. Mitchell, Y. Wang, P.D. Martin The effect of gemfibrozil on the pharmacokinetics of rosuvastatin Clin Pharmacol Ther 75 2004 455 463
8. M. Hirano, K. Maeda, S. Matsushima, Y. Nozaki, H. Kusuhara, Y. Sugiyama Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin Mol Pharmacol 68 2005 800 807
9. K.J. Cooper, P.D. Martin, A.L. Dane, M.J. Warwick, A. Raza, D.W. Schneck Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects Br J Clin Pharmacol 55 2003 94 99
10. R.B. Kim 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter what's it all about? Clin Pharmacol Ther 75 2004 381 385
11. Y. Nishizato, I. Ieiri, H. Suzuki, M. Kimura, K. Kawabata, T. Hirota Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes consequences for pravastatin pharmacokinetics Clin Pharmacol Ther 73 2003 554 565
12. J. Mwinyi, A. Johne, S. Bauer, I. Roots, T. Gerloff Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics Clin Pharmacol Ther 75 2004 415 421
13. M. Niemi, E. Schaeffeler, T. Lang, M.F. Fromm, M. Neuvonen, C. Kyrklund High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1) Pharmacogenetics 14 2004 429 440
14. R.G. Tirona, B.F. Leake, G. Merino, R.B. Kim Polymorphisms in OATP-C. Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans J Biol Chem 276 2001 35669 35675
15. R.G. Tirona, B.F. Leake, A.W. Wolkoff, R.B. Kim Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation J Pharmacol Exp Ther 304 2003 223 228
16. M. Iwai, H. Suzuki, I. Ieiri, K. Otsubo, Y. Sugiyama Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C) Pharmacogenetics 14 2004 749 757
17. Y. Kameyama, K. Yamashita, K. Kobayashi, M. Hosokawa, K. Chiba Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1* (*)5, SLCO1B1* (*)15 and SLCO1B1* (*)15+C1007G, by using transient expression systems of HeLa and HEK293 cells Pharmacogenet Genomics 15 2005 513 522
18. T. Nozawa, H. Minami, S. Sugiura, A. Tsuji, I. Tamai Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin in vitro evidence and effect of single nucleotide polymorphisms Drug Metab Dispos 33 2005 434 439
19. J. Kirchheiner, J. Brockmoller Clinical consequences of cytochrome P450 2C9 polymorphisms Clin Pharmacol Ther 77 2005 1 16
20. C. Guillemette Pharmacogenomics of human UDP-glucuronosyltransferase enzymes Pharmacogenomics J 3 2003 136 158
21. C.P. Zamber, J.K. Lamba, K. Yasuda, J. Farnum, K. Thummel, J.D. Schuetz Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine Pharmacogenetics 13 2003 19 28
22. W. Muck, S. Unger, K. Kawano, G. Ahr Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin Br J Clin Pharmacol 45 1998 583 590
23. J. Kirchheiner, D. Kudlicz, C. Meisel, S. Bauer, I. Meineke, I. Roots Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers Clin Pharmacol Ther 74 2003 186 194
24. K. Kajinami, N. Takekoshi, M.E. Brousseau, E.J. Schaefer Pharmacogenetics of HMG-CoA reductase inhibitors exploring the potential for genotype-based individualization of coronary heart disease management Atherosclerosis 177 2004 219 234
25. D.I. Chasman, D. Posada, L. Subrahmanyan, N.R. Cook, V.P. Stanton Jr, P.M. Ridker Pharmacogenetic study of statin therapy and cholesterol reduction JAMA 291 2004 2821 2827
26. A.B. Mulder, H.J. van Lijf, M.A. Bon, F.A. van den Bergh, D.J. Touw, C. Neef Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin Clin Pharmacol Ther 70 2001 546 551
27. K. Kajinami, M.E. Brousseau, J.M. Ordovas, E.J. Schaefer CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia Am J Cardiol 93 2004 104 107
28. K. Kajinami, M.E. Brousseau, J.M. Ordovas, E.J. Schaefer Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner Am J Cardiol 93 2004 1046 1050
29. K.T. Kivisto, M. Niemi, E. Schaeffeler, K. Pitkala, R. Tilvis, M.F. Fromm Lipid-lowering response to statins is affected by CYP3A5 polymorphism Pharmacogenetics 14 2004 523 525
30. A. Wang, B.N. Yu, C.H. Luo, Z.R. Tan, G. Zhou, L.S. Wang Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients Eur J Clin Pharmacol 60 2005 843 848
31. J. Geisel, K.T. Kivisto, E.U. Griese, M. Eichelbaum The efficacy of simvastatin is not influenced by CYP2D6 polymorphism Clin Pharmacol Ther 72 2002 595 596
32. R. Tachibana-Iimori, Y. Tabara, H. Kusuhara, K. Kohara, R. Kawamoto, J. Nakura Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors Drug Metab Pharmacokinet 19 2004 375 380
33. X. Wu, L.R. Whitfield, B.H. Stewart Atorvastatin transport in the Caco-2 cell model contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter Pharm Res 17 2000 209 215
34. K.T. Kivisto, J. Zukunft, U. Hofmann, M. Niemi, S. Rekersbrink, S. Schneider Characterisation of cerivastatin as a P-glycoprotein substrate studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice Naunyn Schmiedebergs Arch Pharmacol 370 2004 124 130
35. J.H. Hochman, N. Pudvah, J. Qiu, M. Yamazaki, C. Tang, J.H. Lin Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin Pharm Res 21 2004 1686 1691
36. M. Sasaki, H. Suzuki, K. Ito, T. Abe, Y. Sugiyama Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and multidrug resistance-associated protein 2 (MRP2/ABCC2) J Biol Chem 277 2002 6497 6503
37. M. Hirano, K. Maeda, H. Hayashi, H. Kusuhara, Y. Sugiyama Bile salt export pump (BSEP/ABCB11) can transport a non-bile acid substrate, pravastatin J Pharmacol Exp Ther 314 2005 876 882
38. Y. Shitara, M. Hirano, H. Sato, Y. Sugiyama Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil J Pharmacol Exp Ther 311 2004 228 236
39. H. Fujino, D. Nakai, R. Nakagomi, M. Saito, T. Tokui, J. Kojima Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase Arzneimittelforschung 54 2004 382 388
40. B. Hsiang, Y. Zhu, Z. Wang, Y. Wu, V. Sasseville, W.P. Yang A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters J Biol Chem 274 1999 37161 37168
41. M. Hirano, K. Maeda, Y. Shitara, Y. Sugiyama Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans J Pharmacol Exp Ther 311 2004 139 146
42. D. Kobayashi, T. Nozawa, K. Imai, J. Nezu, A. Tsuji, I. Tamai Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane J Pharmacol Exp Ther 306 2003 703 708
43. M. Takeda, R. Noshiro, M.L. Onozato, A. Tojo, H. Hasannejad, X.L. Huang Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors Eur J Pharmacol 483 2004 133 138
44. I. Tamai, H. Takanaga, H. Maeda, Y. Sai, T. Ogihara, H. Higashida Participation of a proton-cotransporter, MCT1, in the intestinal transport of monocarboxylic acids Biochem Biophys Res Commun 214 1995 482 489
45. K. Nagasawa, K. Nagai, A. Ishimoto, S. Fujimoto Transport mechanism for lovastatin acid in bovine kidney NBL-1 cells kinetic evidences imply involvement of monocarboxylate transporter 4 Int J Pharm 262 2003 63 73